| Literature DB >> 26912175 |
Régine Kiasuwa Mbengi1,2, Renée Otter3, Katrien Mortelmans4, Marc Arbyn5,6, Herman Van Oyen7, Catherine Bouland8, Christophe de Brouwer9.
Abstract
BACKGROUND: The spread of early detection and the improvement of cancer treatment have led to an increased prevalence of cancer survivors, including in the working age population. Return-to-work (RTW) of cancer survivors has become a key issue for national cancer control plans. This study aims (1) to identify the factors that have an impact on RTW of cancer survivors and to draw a risk profile supporting health professionals in the screening of those at risk for barriers of RTW and (2) to sharpen these results with input from health, social security and academic Belgian experts and to provide evidence-based recommendations that facilitate RTW of cancer survivors.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26912175 PMCID: PMC4765094 DOI: 10.1186/s13643-016-0210-z
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Fig. 1Age-specific incidence rate in males and females in Belgium, 2011 (n/100,000 person years). Belgian Cancer Registry
Fig. 2The stepwise approach followed to conduct the rapid review. Adapted from Arksey and O’Malley [8] and Khangura et al. [7]
Fig. 3The PRISMA flow chart of included studies
Summary of results from the literature: risk factors, relevance of studies and main results
| Factors |
|
| Relevance | Results | ||
|---|---|---|---|---|---|---|
| High (low risk of bias) | Moderate (unclear risk of bias) | Low (high risk of bias) | ||||
| Socio-demographic | ||||||
| Age | 19 | 12 | 4 | 4 | 4 | Women aged ≥50 and men aged ≥55 are more at risk. |
| Education or income | 15 | 9 | 3 | 3 | 3 | Low educational and income levels predict prolonged time to RTW. |
| Disease and treatment-related | ||||||
| Cancer site | 13 | 11 | 3 | 4 | 4 | Head and neck, lung and breast cancers and leukaemia impede RTW. |
| Stage | 7 | 6 | 1 | 3 | 2 | Advanced cancer stages substantially lengthen sickness leave. |
| Treatment | 21 | 18 | 1 | 9 | 8 | Chemotherapy and combination of therapies are negatively associated with RTW. |
| Symptoms | 11 | 11 | 0 | 6 | 5 | Fatigue, pain and depression are the main impeding symptoms. |
| Work-related | ||||||
| Type, sector and job demands | 13 | 12 | 4 | 4 | 4 | Lower occupational class, private sector and demanding jobs impede the (time to) RTW. |
| Employers’ and colleagues’ support | 7 | 7 | 0 | 0 | 7 | Support of colleagues and employers predict quicker and easier RTW. |
| Personal and subjective | ||||||
| Value of work | 7 | 7 | 1 | 1 | 5 | The (re)evaluation of the importance of paid work substantially affects the choice to RTW. |
| Total | 43 | 10 | 19 | 14 | ||
Criteria to assess the relevance of studies included in the analysis
| Categories | Criteria | Points |
|---|---|---|
| Internal validity | Generalities | |
| Is the hypothesis/aim/objective of the study clearly described? | 3 | |
| Are the main findings/results/outcomes clearly described? | 3 | |
| Are the characteristics of the patients included described? | (3) | |
| Socio-demographic | 1 | |
| Disease/treatment-related | 1 | |
| Work-related | 1 | |
| Study design and methods | ||
| Data collection | ||
| Population-based | 3 | |
| Regionally based (or several settings) | 2 | |
| Hospital/centre-based | 1 | |
| Were the groups equivalent at baseline (or adjusted)? | (3) | |
| Socio-demographic characteristics | 1.5 | |
| Work-related characteristics | 1.5 | |
| Number subjects included | ||
| ≥500 | 3 | |
| ≥50, <500 | 2 | |
| <50 | 1 | |
| Length of follow-up (since diagnosis or treatment) | ||
| ≥1 year | 3 | |
| ≥6 months | 2 | |
| ≥3 months | 1 | |
| Loss of follow-up = less than 5 % | 2 | |
| External validity | Number of cancer sites | |
| >10 | 3 | |
| 4–10 | 2 | |
| ≥3 | 1 | |
| Were the subjects representative of the population from which they were recruited? | 3 | |
| Total (maximum) | 29 |
List of experts having participated in the Delphi sessions
| Participants | Institution | Position |
|---|---|---|
| Governmental | ||
| National Institute for Health and Disability Insurance (NIHDI) | Director | |
| 2 | NIHDI | Civil servant (officer) |
| Federal Public Service (Ministry) Public Health | Civil servant (officer) | |
| 2 | Federal Public Service (Ministry) Employment | Civil servant (officer) |
| Sickness funds | ||
| Christelijke Mutualiteit (CM) | Medical advisor for the CM | |
| University hospitals | ||
| 2 | UZ Gent | Psycho-oncologist |
| Cliniques universitaires Saint Luc | Psychologist | |
| Cliniques universitaires Saint Luc | Coordinator of oncological care | |
| Cliniques universitaires Saint Luc | Psycho-oncologist | |
| Institut Jules Bordet | Coordinator of oncological care (nurse) | |
| Institut Jules Bordet | Occupational therapist | |
| Institut Jules Bordet | Oncologist | |
| Hôpital Universitaire Erasme (ULB) | Physiotherapist | |
| KU Leuven, Occupational, Environmental and Insurance Medicine | Researcher, PhD | |
| KU Leuven, Institute of Labour Law | Research assistant, PhD | |
| ULg, Occupational Health and Health Education | Professor of occupational medicine | |
| ULg, Occupational Health and Health Education | PhD student, occupational health | |
| HELB, Occupational Therapy | Occupational therapist, professor | |
| General hospital | ||
| CHC de Liège | Oncologist | |
| Patient’s associations and foundations | ||
| Vlaams Liga Tegen Kanker (VLK), Flemish League Against Cancer | Collaborator knowledge and policy | |
| Patienten Rat & Treff, German League for Patient’s Rights | Collaborator | |
| Belgian Cancer Foundation | Knowledge manager, PhD Social Sciences | |
| Cédric-Hèle Institute, Flemish Institute for Psycho-oncology | Collaborator |